Gilead Sciences Inc mentioned on Tuesday it was in discussions with chemical and drug producers to supply its experimental COVID-19 drug remdesivir for Europe, Asia and the creating world via at the very least 2022.
The drugmaker didn’t disclose particulars in regards to the firms.
With a number of international locations throughout the globe reeling from the virus outbreak, curiosity in remdesivir has been excessive as there are presently no accepted remedies or vaccines for COVID-19, the respiratory sickness attributable to the brand new coronavirus.
Gilead final week acquired the US Meals and Drug Administration’s emergency use authorization for utilizing remdesivir as a remedy towards COVID-19, after the drugmaker offered knowledge displaying the drug had helped COVID-19 sufferers.
Gilead additionally mentioned on Tuesday it was negotiating long-term licenses with a number of generic drugmakers in India and Pakistan to supply remdesivir for creating international locations and that it will present know-how to help the manufacturing.
Considered one of Bangladesh’s largest drugmakers, Beximco Prescribed drugs, will begin remdesivir manufacturing this month, Reuters reported on Tuesday, citing a senior firm government.
Remdesivir was beforehand out there just for sufferers enrolled in medical trials or these cleared to get the drug beneath expanded use and compassionate use applications.
Gilead, which has already mentioned it would donate the primary 1.5 million doses of remdesivir, additionally beforehand mentioned it was centered on making the drug accessible and reasonably priced to as many individuals as attainable upon approval.
Gilead mentioned it was working to construct a consortium of producing companions to assist maximize international provide of the drug, which requires scarce uncooked supplies and specialised manufacturing capabilities with restricted international capability.
The corporate additionally mentioned it was in superior talks with UNICEF to ship remdesivir utilizing the company’s distribution networks.
(Apart from the headline, this story has not been edited by NDTV employees and is printed from a syndicated feed.)